Copenhagen Oe

• A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers Recruiting
  2023-505165-93-00 1 2024-03-01 Non-Hodgkin Lymphoid Malignancies
• Open-Label Extension of EDG-5506 in Participants with Becker Muscular Dystrophy Recruiting
  2023-506231-15-00 4 2024-02-22 Becker Muscular Dystrophy
• Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting
  2022-503126-12-01 5 2024-01-05 Hypoparathyroidism
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting
  2023-506464-14-00 9 2023-06-29 Advanced solid tumors
• Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta … Recruiting
  2023-503322-39-00 3 2023-06-16 Newly diagnosed patients with metastatic (other than lung/pleura metas
• Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting
  2022-500266-10-00 5 2023-06-13 Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epider
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Recruiting
  2023-509715-91-00 5 2022-05-06 Fabry’s disease
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T … Recruiting
  2023-504084-17-00 9 2021-07-12 ALK fusion-positive extracranial solid or primary CNS tumors who have
• TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting
  2024-517606-29-00 5 2020-10-30 Central retinal artery occlusion
• A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl … Recruiting
  2022-501687-18-00 4 2020-10-28 Advanced malignancies and IAI diseases
• Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting
  2024-516807-17-00 4 2019-01-02 Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
• A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Pri … Recruiting
  2023-508587-29-00 4 2018-04-03 Treatment of high-risk neuroblastoma patients with primary refractory
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 7 2015-01-20 Solid Tumors
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 10 2014-03-27 Acute Lymphoblastic Leukaemia

Showing 121–144 of 671 trials